Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)

Mark G. Kris, Roy S. Herbst, Danny Rischin, Patricia LoRusso, José Baselga, L. A. Hammond, A. Feyereislova, J Ochs, Steven D. Averbuch

Lung Cancer · 2000 · 63 citations · 0 references

Concepts